West Pharmaceutical ServicesWST +1.24%95 EV-to-FCF is 53.67 as of Jun. 28, 2026, which is 14% below its 10-year median of 62.11. GuruFocus rates WST with a GF Score™ of 95/100 and a GF Value™ of $361.62 (Fairly Valued). The stock has 9 warning signs investors should review. Among 419 Medical Devices & Instruments companies, West Pharmaceutical Services ranks worse than 79% on this metric.
The historical rank and industry rank for West Pharmaceutical Services's EV-to-FCF or its related term are showing as below:
WST'
s EV-to-FCF Range Over the Past 10 Years
Min: 34.83 Med: 62.11 Max: 134.16
Current: 53.67
During the past 13 years, the highest EV-to-FCF of West Pharmaceutical Services was 134.16. The lowest was 34.83. And the median was 62.11.
WST's EV-to-FCF is ranked worse than 79% of 419
companies
in the Medical Devices & Instruments industry
Industry Median: 22.67
vs WST: 53.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
West Pharmaceutical Services (NYSE:WST) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
West Pharmaceutical Services's PE Ratio (TTM) for today is calculated as:
West Pharmaceutical Services's share price for today is $350.85.
West Pharmaceutical Services's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
West Pharmaceutical Services EV-to-FCF Related Terms
West Pharmaceutical Services EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
West Pharmaceutical Services EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's EV-to-FCF falls into.
West Pharmaceutical Services's current Enterprise Value is $24,582 Mil.
West Pharmaceutical Services's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $458 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services (WST) has a EV-to-FCF of 53.67 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on West Pharmaceutical Services and its competitors. This is 14% below median its historical median of 62.11. Over the past decade, West Pharmaceutical Services' EV-to-FCF has ranged from 34.83 to 134.16. According to the industry distribution chart, West Pharmaceutical Services ranks #331 out of 419 companies in the Medical Devices & Instruments industry, placing it in the top 79%.
Is West Pharmaceutical Services' EV-to-FCF too high?
West Pharmaceutical Services' current EV-to-FCF of 53.67 is 14% below median its 10-year median of 62.11. Over the past 10 years, this metric has ranged from a low of 34.83 to a high of 134.16. The Medical Devices & Instruments industry median EV-to-FCF is 22.67. West Pharmaceutical Services' value of 53.67 is 136.7% above this industry median. Based on the distribution chart, West Pharmaceutical Services ranks #331 out of 419 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, West Pharmaceutical Services has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' EV-to-FCF compare to RMD and MDLN?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #331 out of 419 companies for EV-to-FCF. This places West Pharmaceutical Services in the lower half of its industry. The industry median EV-to-FCF is 22.67. West Pharmaceutical Services' value of 53.67 is 136.7% above this benchmark. Historically, West Pharmaceutical Services' own EV-to-FCF has ranged from 34.83 to 134.16 over the past decade. While the company's 10-year median is 62.11 vs. the industry median of 22.67, West Pharmaceutical Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.67, based on 419 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. West Pharmaceutical Services's current EV-to-FCF of 53.67 is 136.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on West Pharmaceutical Services and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. West Pharmaceutical Services's current EV-to-FCF is 53.67, which is 14% below median its own 10-year median of 62.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $361.62, compared to a current price of $350.85 — trading 3% below its estimated fair value. The current EV-to-FCF is 53.67, which is 14% below median its 10-year median of 62.11 and 136.7% above the Medical Devices & Instruments industry median of 22.67. West Pharmaceutical Services' overall GF Score™ is 95/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current EV-to-FCF is 53.67 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is West Pharmaceutical Services (WST) Overvalued in 2026?
Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued.
The current stock price of $350.85 is trading 3% below its estimated GF Value™ of $361.62.
GuruFocus considers West Pharmaceutical Services to be Fairly Valued.
Key valuation signals for WST:
EV-to-FCF: 53.67 (14% below median its 10-year median of 62.11)
GF Value™: $361.62 vs. price of $350.85 (3% below fair value)
Industry Position: 136.7% above the Medical Devices & Instruments median (#331 of 419)
No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score
Get the complete analysis for WST
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WST has been successfully added to your 
